|
US3760077A
(en)
|
1969-02-18 |
1973-09-18 |
Cutter Lab |
Injectable compositions of the (plus)-optical isomer of the alpha racemate of 2-(2-ethyl-2-phenyl-1, -dioxolan-4-yl)piperidine and their use
|
|
CH535201A
(de)
|
1969-12-19 |
1973-03-31 |
Bristol Myers Co |
Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
|
|
US4017619A
(en)
|
1973-10-26 |
1977-04-12 |
Burnap Raymond W |
Anesthetic and sedative composition
|
|
EP0424179A3
(en)
|
1989-10-20 |
1991-12-27 |
John William Olney |
Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
|
|
GB9020544D0
(en)
|
1990-09-20 |
1990-10-31 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
|
US5250732A
(en)
|
1991-07-18 |
1993-10-05 |
Genentech, Inc. |
Ketamine analogues for treatment of thrombocytopenia
|
|
US6350784B1
(en)
|
1996-02-12 |
2002-02-26 |
Meryl J. Squires |
Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
|
|
US5854217A
(en)
|
1992-09-28 |
1998-12-29 |
Bearsden Bio, Inc. |
Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
|
|
US5321012A
(en)
|
1993-01-28 |
1994-06-14 |
Virginia Commonwealth University Medical College |
Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
|
|
US5352683A
(en)
|
1993-03-05 |
1994-10-04 |
Virginia Commonwealth University Medical College Of Virginia |
Method for the treatment of chronic pain
|
|
US5897858A
(en)
|
1994-02-03 |
1999-04-27 |
Schering-Plough Healthcare Products, Inc. |
Nasal spray compositions exhibiting increased retention in the nasal cavity
|
|
US5543434A
(en)
|
1994-02-25 |
1996-08-06 |
Weg; Stuart L. |
Nasal administration of ketamine to manage pain
|
|
US5679714A
(en)
|
1995-06-07 |
1997-10-21 |
Weg; Stuart L. |
Administration of ketamine for detoxification and treatment of tobacco addiction
|
|
US5683709A
(en)
|
1994-05-05 |
1997-11-04 |
Ciba Vision Corporation |
Poly(benzalkonium salt) as an anti-microbial agent for aqueous drug compositions
|
|
US5604244A
(en)
|
1995-06-07 |
1997-02-18 |
Alcon Laboratories, Inc. |
Intraocular irrigating solution containing a polyamine antagonist
|
|
US6194415B1
(en)
|
1995-06-28 |
2001-02-27 |
Allergan Sales, Inc. |
Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
|
|
CA2230690C
(en)
|
1995-08-30 |
2008-12-23 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
|
US6197830B1
(en)
|
1995-09-22 |
2001-03-06 |
Bruce M. Frome |
Method for achieving relief from sympathetically mediated pain
|
|
US6441047B2
(en)
|
1995-11-17 |
2002-08-27 |
Alcon Manufacturing Ltd.. |
Combination therapy for treating glaucoma
|
|
DE19601782A1
(de)
|
1996-01-19 |
1997-07-24 |
Merck Patent Gmbh |
Chinolin-2-(1H)one
|
|
US5688830A
(en)
|
1996-01-25 |
1997-11-18 |
Syntex (U.S.A.) Inc. |
Treatment of neuropathic pain
|
|
US6576636B2
(en)
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
|
US5795909A
(en)
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
|
PL189872B1
(pl)
|
1996-07-24 |
2005-10-31 |
Warner Lambert Co |
Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
|
|
US6248789B1
(en)
|
1996-08-29 |
2001-06-19 |
Stuart L. Weg |
Administration of ketamine to manage pain and to reduce drug dependency
|
|
US5919826A
(en)
|
1996-10-24 |
1999-07-06 |
Algos Pharmaceutical Corporation |
Method of alleviating pain
|
|
US20020039594A1
(en)
|
1997-05-13 |
2002-04-04 |
Evan C. Unger |
Solid porous matrices and methods of making and using the same
|
|
US6124282A
(en)
|
1997-05-22 |
2000-09-26 |
Sellers; Edward M. |
Drug formulations
|
|
US5817699A
(en)
|
1997-05-30 |
1998-10-06 |
Flores; John A. |
Process for the preparation of ketamine ointment
|
|
US6329429B1
(en)
|
1997-06-25 |
2001-12-11 |
Warner-Lambert Company |
Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
|
|
FR2772271B1
(fr)
|
1997-12-11 |
2000-09-01 |
Union Pharma Scient Appl |
Nouvelle association pharmaceutique a activite analgesique
|
|
US6391922B1
(en)
|
1998-01-13 |
2002-05-21 |
Synchroneuron, Llc |
Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
|
|
JP2002528416A
(ja)
|
1998-10-27 |
2002-09-03 |
アルコン ラボラトリーズ， インコーポレーテッド |
外網膜の疾患の治療
|
|
AU1602100A
(en)
|
1998-11-25 |
2000-06-13 |
Warner-Lambert Company |
Improved gamma amino butyric acid analogs
|
|
WO2000035876A1
(en)
|
1998-12-18 |
2000-06-22 |
Du Pont Pharmaceuticals Company |
2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity
|
|
US6200990B1
(en)
|
1998-12-21 |
2001-03-13 |
Alcon Laboratories, Inc. |
Neuroprotective agents having antioxidant and NMDA antagonist activity
|
|
US6017961A
(en)
|
1999-07-08 |
2000-01-25 |
Flores; John Anthony |
Ketamine and n-butyl-p-aminobezoate in PLO
|
|
EP1103256A1
(de)
|
1999-11-26 |
2001-05-30 |
Claudius Dr. med. Böck |
Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
|
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
YU41202A
(sh)
|
1999-12-28 |
2005-03-15 |
Pfizer Products Inc. |
Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
|
|
IL152473A0
(en)
|
2000-04-28 |
2003-05-29 |
Sloan Kettering Inst Cancer |
Topical anesthetic/opioid formulations and uses thereof
|
|
US20020013331A1
(en)
|
2000-06-26 |
2002-01-31 |
Williams Robert O. |
Methods and compositions for treating pain of the mucous membrane
|
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
US6878751B1
(en)
|
2000-10-19 |
2005-04-12 |
Imperial College Of Science Technology And Medicine |
Administration of resveratrol to treat inflammatory respiratory disorders
|
|
US20040122090A1
(en)
|
2001-12-07 |
2004-06-24 |
Lipton Stuart A. |
Methods for treating neuropsychiatric disorders with nmda receptor antagonists
|
|
MXPA03004652A
(es)
|
2000-12-21 |
2003-09-05 |
Warner Lambert Co |
Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato.
|
|
WO2002066015A1
(en)
|
2001-02-16 |
2002-08-29 |
Bristol-Myers Squibb Pharma Company |
Use of polyalkylamine polymers in controlled release devices
|
|
ZA200306564B
(en)
|
2001-02-26 |
2004-10-15 |
Optinose As |
Nasal devices.
|
|
US20020198209A1
(en)
|
2001-05-03 |
2002-12-26 |
Allergan Sales Inc. |
Compositions having enhanced pharmacokinetic characteristics
|
|
CA2456806C
(en)
|
2001-08-08 |
2011-10-18 |
Brown University Research Foundation |
Methods for micronization of hydrophobic drugs
|
|
US6638981B2
(en)
|
2001-08-17 |
2003-10-28 |
Epicept Corporation |
Topical compositions and methods for treating pain
|
|
GB0207422D0
(en)
|
2002-03-28 |
2002-05-08 |
Optinose As |
Nasal devices
|
|
GB0209494D0
(en)
|
2002-04-25 |
2002-06-05 |
Optinose As |
Nasal devices
|
|
US20040039352A1
(en)
|
2002-06-28 |
2004-02-26 |
Paul Bergeson |
Nasal dosing device
|
|
GB0215270D0
(en)
|
2002-07-02 |
2002-08-14 |
Optinose As |
Nasal devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
EP1558231A4
(en)
|
2002-10-03 |
2010-09-08 |
Cypress Bioscience Inc |
DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
|
|
DE10306686A1
(de)
|
2003-02-12 |
2004-08-26 |
Ing. Erich Pfeiffer Gmbh |
Austragvorrichtung zur manuellen Erzeugung eines Volumenstroms
|
|
US20040266808A1
(en)
|
2003-06-27 |
2004-12-30 |
Kamen Barton A. |
Treatment of antifolate neurotoxicity
|
|
GB0319119D0
(en)
|
2003-08-14 |
2003-09-17 |
Optinose As |
Delivery devices
|
|
WO2005058911A2
(en)
|
2003-12-15 |
2005-06-30 |
Alcon, Inc. |
Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
|
|
WO2005079756A2
(en)
|
2004-02-13 |
2005-09-01 |
Neuromolecular, Inc. |
Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
|
|
US20050222270A1
(en)
|
2004-02-26 |
2005-10-06 |
Olney John W |
Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
|
|
GB0420513D0
(en)
|
2004-09-15 |
2004-10-20 |
Optinose As |
Powder delivery devices
|
|
AU2004100927B4
(en)
|
2004-11-01 |
2005-03-24 |
Richard Benson |
Snorenomore (anti-snoring device)
|
|
GB0503738D0
(en)
|
2005-02-23 |
2005-03-30 |
Optinose As |
Powder delivery devices
|
|
GB0604444D0
(en)
|
2006-03-06 |
2006-04-12 |
Optinose As |
Nasal devices
|
|
AU2007229866A1
(en)
|
2006-03-22 |
2007-10-04 |
Mount Sinai School Of Medicine |
Intranasal administration of ketamine to treat depression
|
|
US7506649B2
(en)
|
2006-06-07 |
2009-03-24 |
Ventus Medical, Inc. |
Nasal devices
|
|
US8607228B2
(en)
|
2006-08-08 |
2013-12-10 |
Intel Corporation |
Virtualizing performance counters
|
|
GB0623732D0
(en)
|
2006-11-28 |
2007-01-10 |
Optinose As |
Powder delivery devices
|
|
GB2448193A
(en)
|
2007-04-05 |
2008-10-08 |
Optinose As |
Nasal delivery device
|
|
BRPI0809843A2
(pt)
|
2007-04-26 |
2014-09-23 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica e uso de um composto"
|
|
AU2008279169A1
(en)
|
2007-07-23 |
2009-01-29 |
Biotie Therapies, Inc |
4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
|
|
GB0719299D0
(en)
|
2007-10-03 |
2007-11-14 |
Optinose As |
Nasal delivery devices
|
|
TW201029689A
(en)
|
2008-11-03 |
2010-08-16 |
Schering Corp |
Elastomeric discharge member for nasal delivery device
|
|
US20110038807A1
(en)
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
|
US8875711B2
(en)
|
2010-05-27 |
2014-11-04 |
Theravent, Inc. |
Layered nasal respiratory devices
|
|
AP2012006639A0
(en)
|
2010-06-04 |
2012-12-31 |
Us Gov Ct Disease Contr & Prev |
Nasal aerosol delivery system
|
|
JP3193069U
(ja)
|
2010-09-02 |
2014-09-18 |
シプノーズ リミテッド |
経鼻投与装置
|
|
GB201015371D0
(en)
|
2010-09-14 |
2010-10-27 |
Optinose As |
Nasal delivery
|
|
WO2012123819A1
(en)
|
2011-03-15 |
2012-09-20 |
Optinose As Et Al |
Nasal delivery
|
|
US8791091B2
(en)
|
2011-12-02 |
2014-07-29 |
Bristol-Myers Squibb Company |
Aryl dihydropyridinone and piperidinone MGAT2 inhibitors
|
|
PL2817054T3
(pl)
|
2012-02-24 |
2020-12-14 |
Optinose As |
Donosowe urządzenia podające
|
|
PL2817052T3
(pl)
|
2012-02-24 |
2018-01-31 |
Optinose As |
Urządzenia do podawania donosowego
|
|
CA2865355C
(en)
|
2012-02-24 |
2021-02-16 |
Optinose As |
Nasal delivery devices
|
|
WO2013128447A1
(en)
|
2012-02-28 |
2013-09-06 |
Sipnose Ltd. |
Nasal delivery device
|
|
ES1076654Y
(es)
|
2012-03-15 |
2012-07-03 |
Garcia Miguel Ramon Guillem |
Aspirador nasal.
|
|
KR20150096370A
(ko)
|
2012-08-23 |
2015-08-24 |
스튜어트 엘. 웨그 |
항불안제 조성물, 제형 및 사용방법
|
|
FR3003481B1
(fr)
|
2013-03-19 |
2020-05-15 |
Aptar France Sas |
Dispositif de distribution de produit fluide.
|
|
US10596334B2
(en)
|
2013-04-04 |
2020-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nasal aerosol delivery system
|
|
DK2983787T3
(da)
|
2013-04-12 |
2020-01-06 |
Icahn School Med Mount Sinai |
Fremgangsmåde til behandling af posttraumatisk stresssygdom
|
|
FR3016123B1
(fr)
|
2014-01-03 |
2016-02-05 |
Georges Creps |
Dispositif nasal ambulatoire ameliore
|
|
AU2015318123A1
(en)
|
2014-09-15 |
2017-03-30 |
Janssen Pharmaceutica Nv |
Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
WO2016109427A1
(en)
|
2014-12-31 |
2016-07-07 |
Icahn School Of Medicine At Mount Sinai |
Method of maintaining the anti-depressant effect of ketamine with lithium
|
|
US20160199599A1
(en)
|
2015-01-13 |
2016-07-14 |
Bhl Patent Holdings Llc |
Nasal Delivery Device and Methods of Use
|
|
WO2016172672A1
(en)
*
|
2015-04-24 |
2016-10-27 |
Icahn School Of Medicine At Mount Sinai |
Method for treating suicidal ideation
|
|
US20160361507A1
(en)
|
2015-06-11 |
2016-12-15 |
Bruce H. Levin |
Nasal Delivery Device and Methods of Use
|
|
AU2016302387B2
(en)
|
2015-07-31 |
2020-12-24 |
Asap Breatheassist Pty Ltd |
Nasal devices
|
|
MX2018002895A
(es)
|
2015-09-10 |
2018-07-06 |
Impel Neuropharma Inc |
Dispositivo de administracion nasal en linea.
|
|
US10940274B2
(en)
|
2015-12-01 |
2021-03-09 |
Cipla Limited |
Nasal spray assembly
|
|
FR3046552B1
(fr)
|
2016-01-07 |
2018-02-16 |
Aptar France Sas |
Dispositif de distribution nasale de poudre.
|
|
EP3426329A4
(en)
|
2016-03-09 |
2019-11-13 |
Proveris Scientific Corporation |
METHOD FOR MEASURING THE UNITABILITY OF THE DOSE CONTENT OF INHALATION AND NOSING DEVICES
|
|
CN110177545A
(zh)
|
2016-11-16 |
2019-08-27 |
爱尔兰詹森科学公司 |
用于预防上呼吸道感染的聚肌苷酸和聚胞苷酸的制剂
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
US20180256867A1
(en)
|
2017-03-07 |
2018-09-13 |
Bruce H. Levin |
Nasal Delivery Device and Methods of Use
|
|
SE542541C2
(en)
|
2017-05-12 |
2020-06-02 |
Noseoption Ab |
Nasal device
|
|
WO2019077586A1
(en)
|
2017-10-20 |
2019-04-25 |
Beck Medical, Ltd. |
NASAL DEVICE FOR TREATMENT
|
|
TWI660756B
(zh)
|
2018-05-22 |
2019-06-01 |
蔡淑真 |
Nasal inserter
|
|
TWI673076B
(zh)
|
2018-12-28 |
2019-10-01 |
蔡淑真 |
鼻腔插入器
|
|
JP2022524008A
(ja)
|
2019-03-05 |
2022-04-27 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
うつ病の治療のためのエスケタミン
|
|
CA3133012A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
JP2023511370A
(ja)
|
2020-01-22 |
2023-03-17 |
シーロス セラピューティクス， インコーポレイテッド |
Ｎｍｄａ拮抗薬の副作用の低減
|
|
TW202310825A
(zh)
|
2021-05-14 |
2023-03-16 |
美商西羅斯醫療公司 |
減少ｎｍｄａ受體拮抗劑之副作用
|
|
US20240261236A1
(en)
|
2021-05-14 |
2024-08-08 |
Seelos Therapeutics, Inc. |
Methods of using nmda receptor antagonists
|